Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALRN 6924

Drug Profile

ALRN 6924

Alternative Names: ALRN-6924

Latest Information Update: 25 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Aileron Therapeutics; Dana-Farber Cancer Institute
  • Class Antineoplastics; Immunotherapies; Peptides
  • Mechanism of Action Proto-oncogene protein c-mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Chemotherapy-induced damage; Haematological malignancies; Myelodysplastic syndromes; Radiation injuries; Solid tumours

Most Recent Events

  • 17 Jul 2023 Aileron Therapeutics completes a phase I trial in Haematological malignancies and Solid tumours (In infants, In children, In adults, In adolescents, Second-line therapy or greater, Monotherapy, Combination therapy) in USA (IV) (NCT03654716)
  • 23 Feb 2023 Discontinued - Phase-I for Breast cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 23 Feb 2023 Discontinued - Phase-I for Chemotherapy-induced damage (Prevention) in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top